The above experiment results indicated that HSP90 inhibitor 17AAG combined with the inhibitor of protein nucleus export LMB could enhance the killing ability when targeting CML cells. Here, HSP90AA1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.